Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 747 of 5804
-
Could inhaled gases help COVID-19 patients breathe easier and survive?
Disease control OngoingPatients suffering lung failure, possibly from COVID-19 or hypoxic lung failure, will need life-saving support from a breathing machine. Any patient needing this support requires drugs to keep them sleepy, or "sedated" to be comfortable on this machine. Sedation is made possible …
Phase: PHASE3 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New combo therapy aims to shrink melanoma before surgery
Disease control OngoingThe purpose of this study is to test the effects of anti-PI-1 inhibitor (TSR-042) or anti-PD-1/anti-TIM-3 combination (TSR-042 / TSR-022) in patients with operable melanoma.
Phase: PHASE2 • Sponsor: Diwakar Davar • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
New hope for hard-to-treat lymphoma: targeted drug combo tested in large trial
Disease control OngoingThe participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' …
Phase: PHASE3 • Sponsor: Epizyme, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Could a week of antibiotics stop joint infections after replacement surgery?
Disease control ENROLLING_BY_INVITATIONTo determine the effectiveness of a 7-day course of an oral, prophylactic antibiotic on the incidence of periprosthetic joint infection and wound complications following primary total hip and knee arthroplasty in a high-risk patient population.
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New MRI clue could slash MS misdiagnosis rates
Diagnosis OngoingThe need for improved diagnostic methods in Multiple Sclerosis (MS) is widely recognized. Although Magnetic Resonance Imaging (MRI) is a longstanding tool for detecting MS lesions, diagnostic inaccuracies persist. Up to 20% of people diagnosed with MS (1 in 5) are later found not…
Sponsor: The Cleveland Clinic • Aim: Diagnosis
Last updated Jun 27, 2026 07:52 UTC
-
Could cheap heart drugs save lives from pesticide poisoning?
Disease control CompletedThis study evaluates whether the addition of intravenous magnesium sulphate or nimodipine to standard therapy (supportive care plus for all patients atropine and, for OP insecticide poisoned patients, pralidoxime) benefits patients after acute anticholinesterase self-poisoning wi…
Phase: PHASE3 • Sponsor: University of Edinburgh • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New drug combo shows promise against resistant ovarian cancer
Disease control CompletedAfuresertib is an AKT inhibitor, a new class of agents under development that may provide physicians with a new clinical option to control platinum resistant ovarian cancer (PROC) progression. Afuresertib plus chemotherapy has demonstrated anti-tumor efficacy and an acceptable sa…
Phase: PHASE2 • Sponsor: Laekna Limited • Aim: Disease control
Last updated Jun 26, 2026 15:45 UTC
-
New drug combo aims to tackle Hard-to-Treat myeloma
Disease control OngoingThe primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with nirogacestat and to establish the recommended Phase 2 dose for combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is …
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Promising targeted therapy for tough breast cancer hits roadblock
Disease control TerminatedThe purpose of this study was to determine whether treatment with alpelisib in combination with nab-paclitaxel is safe and effective in subjects with advanced triple negative breast cancer (aTNBC) who carry either a PIK3CA mutation (Study Part A) or have PTEN loss (Study Part B1)…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New triple therapy shows promise for Tough-to-Treat lung cancer
Disease control OngoingThis phase 2 trial will evaluate the safety and efficacy of combining immunotherapy with a PD-1 checkpoint inhibitor (Pembrolizumab), an anti-VEGF receptor (Ramucirumab), and a taxane chemotherapy (Docetaxel) in treating patients with non-small cell lung cancer (NSCLC) who did no…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Immunotherapy after Chemo-Radiation shows promise for rare throat cancer
Disease control CompletedPatients will be treated with pembrolizumab after concurrent chemoradiotherapy with cisplatin. Patients will be treated with up to 17 cycles (approximately 1 year) of pembrolizumab until disease progression or recurrence
Phase: PHASE2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
New shot could stop GPP flares before they start
Prevention CompletedThis is a study in adolescents and adults with Generalized Pustular Psoriasis (GPP). People between 12 and 75 years old can take part in the study. The study is open to people who had GPP flare-ups in the past but whose skin is clear or almost clear when they join the study. The …
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Prevention
Last updated Jun 27, 2026 07:55 UTC
-
New hope for stomach cancer: targeted drug combo trial launches
Disease control Recruiting nowDESTINY-Gastric03 will investigate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of trastuzumab deruxtecan (T-DXd) alone or in combination with chemotherapy and/or immunotherapy in HER2-expressing advanced/metastatic gastric/gastro…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug shows promise for Long-Term platelet control in rare bleeding disorder
Disease control CompletedThis is an open-label long-term multicenter phase 3 trial to evaluate the efficacy and safety of ARGX-113 in adult patients with primary ITP.
Phase: PHASE3 • Sponsor: argenx • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for kids with rare cancer: sirolimus combo shows promise
Disease control CompletedRemarkable progress has been made in treating germ-cell tumor (GCT) through the use of platinum-based regimens. However, part of yolk sac tumor (YST) with cisplatin resistance or recurrence is nevertheless prone to relapse after second-line treatment. This leaves a gap in effecti…
Phase: PHASE2, PHASE3 • Sponsor: Shandong First Medical University • Aim: Disease control
Last updated Jun 26, 2026 19:11 UTC
-
Can CBD tame severe autism behaviors? new study investigates
Symptom relief OngoingThere are very few treatments that are effective in reducing severe behavioral problems associated with autism. These behaviors include aggressive and self-harm behaviors, frequent repetitive behaviors and severe hyperactivity. This study is being conducted to determine whether c…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Symptom relief
Last updated Jun 27, 2026 07:52 UTC
-
New drug may let people with rare sun allergy enjoy the outdoors longer
Symptom relief CompletedThe primary objective of this study is to investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP aged 12-75.
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 08:07 UTC
-
Can a rheumatoid arthritis drug save COVID-19 patients from lung failure?
Disease control OngoingA phase II clinical trial will be carried out with the objective of studying the impact of the administration of Tocilizumab on the evolution of the acute respiratory distress syndrome (ARDS) in patients with severe or critical SARS-CoV-2 infection. Due to the high mortality of s…
Phase: PHASE2 • Sponsor: Instituto Nacional de Cancerologia de Mexico • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Immunotherapy combo shows promise against Early-Stage lung cancer
Disease control OngoingThe primary objective of this study is to evaluate and compare major pathological response(MPR) rate and event-free survival (EFS) in participants receiving tislelizumab plus platinum-based doublet chemotherapy as the new additional treatment followed by tislelizumab as adjuvant …
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New drug cocktail targets rare blood cancer in promising trial
Disease control Recruiting nowThis phase II trial studies how well venetoclax, SL-401, and chemotherapy works in treating patients with blastic plasmacytoid dendritic cell neoplasm. Venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. SL-401 is a recombinant pr…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC